Climb Bio, Inc.

XNASHealth care

Last traded price · USD

$9.28

−0.54%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $9.33
Volume: 611
Day's high: —
Day's low: —

In brief

Climb Bio, Inc. is a health care company listed on Nasdaq, valued at about $533M.
Its shares closed at $9.33 on 4 Nov 2026, up 396.3% over the past year.
From India you can buy CLYM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Climb Bio, Inc. (CLYM) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole CLYM share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade CLYM options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −12.6% (SPY −1.6%, XLV +13.5%). 3 months: −25.2% (SPY −0.4%, XLV +15.5%). 1 year: +396.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CLYM, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $9.33 was 23.2% below its 50-day average ($12.15) and 10.8% below its 200-day average ($10.46). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 5 Sep 2025, 293 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.3 days to cover short interest
9.8M shares were sold short at the 15 Oct 2026 settlement, 17.0% of the 57.4M shares outstanding; covering them would take 10.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
46% of the way up its 52-week range
Closed at $9.33 on 4 Nov 2026: 49.1% below the 52-week high of $18.33 (25 Aug 2026) and 470.6% above the low of $1.64 (3 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−12.6%

6 months−23.6%

1 year+396.3%

5 years—

Newswire

About

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Website

Notable moves

December 16, 2025
+21.26%
December 15, 2025
+27.00%
December 12, 2025
+30.43%

Climb Bio, Inc.

XNASHealth care

Last traded price · USD

$9.28

−0.54%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $9.33
Volume: 611
Day's high: —
Day's low: —

In brief

Climb Bio, Inc. is a health care company listed on Nasdaq, valued at about $533M.
Its shares closed at $9.33 on 4 Nov 2026, up 396.3% over the past year.
From India you can buy CLYM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Climb Bio, Inc. (CLYM) shares from India?

Do I need the price of a whole CLYM share to invest?

How much can I invest in US stocks in a year?

Can I trade CLYM options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −12.6% (SPY −1.6%, XLV +13.5%). 3 months: −25.2% (SPY −0.4%, XLV +15.5%). 1 year: +396.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CLYM, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $9.33 was 23.2% below its 50-day average ($12.15) and 10.8% below its 200-day average ($10.46). It has closed below the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 5 Sep 2025, 293 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.3 days to cover short interest
9.8M shares were sold short at the 15 Oct 2026 settlement, 17.0% of the 57.4M shares outstanding; covering them would take 10.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
46% of the way up its 52-week range
Closed at $9.33 on 4 Nov 2026: 49.1% below the 52-week high of $18.33 (25 Aug 2026) and 470.6% above the low of $1.64 (3 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−12.6%

6 months−23.6%

1 year+396.3%

5 years—

Newswire

About

Website

Notable moves

December 16, 2025
+21.26%
December 15, 2025
+27.00%
December 12, 2025
+30.43%

Climb Bio, Inc.

Climb Bio, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

10.3 days to cover short interest

46% of the way up its 52-week range

Climb Bio, Inc.

Climb Bio, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

10.3 days to cover short interest

46% of the way up its 52-week range